Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||DT2216 + S63845|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DT2216||BCL-XL inhibitor 11||DT2216 is a small molecule proteolysis-targeted chimera (PROTAC) that binds to BCL-XL and targets it for degradation, potentially resulting in decreased tumor growth (PMID: 31792461).|
|S63845||MCL1 Inhibitor 14||S63845 is a small molecule binds to and inhibits Mcl1, leading to apoptosis in tumor cells (PMID: 27760111).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||DT2216 + S63845||Preclinical - Cell culture||Actionable||In a preclinical study, the combination of DT2216 and S63845 demonstrated synergy in a myeloma cell line dependent on MCL-1 and BCL-XL for survival, resulting in decreased cell viability in culture (PMID: 31792461).||31792461|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|